Wide Ranks

BFRI

Biofrontera Inc.

0.9900

Top Statistics
Market Cap 7 M Forward PE -0.8609 Revenue Growth 34.00 %
Current Ratio 1.89 Trailing PE 0.8534 Earnings Growth 0.00 %
Profit Margins -38.34 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.0520 Enterprise / Revenue 0.0270 Price To Sales Trailing12 Months 0.2177
Profitability
Profit Margins -38.34 % Operating Margins -64.69 %
Balance Sheet
Total Cash 4 M Total Cash Per Share 0.7920 Total Debt 1 M
Total Debt To Equity 13.20 Current Ratio 1.89 Book Value Per Share 3.16
All Measures
Short Ratio 8.00 % Message Board Id finmb_531568773 Shares Short Prior Month 200639
Return On Equity -1.49 City Woburn Uuid f81dad8d-7768-38b3-a53c-f0f095b62379
Previous Close 1.02 First Trade Date Epoch Utc 1 B Book Value 3.16
Beta 0.5090 Total Debt 1 M Volume 605231
Price To Book 0.3135 Last Split Date 1 B Fifty Two Week Low 0.6100
Total Cash Per Share 0.7920 Total Revenue 35 M Shares Short Previous Month Date 1 B
Target Median Price 11.50 Max Age 86400 Recommendation Mean 1.50
Sand P52 Week Change 0.3133 Operating Margins -64.69 % Target Mean Price 11.50
Net Income To Common -13510000 Short Percent Of Float 0.0826 Implied Shares Outstanding 7 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 4 M Next Fiscal Year End 1 B
Revenue Per Share 11.57 Held Percent Insiders 0.3206 Ebitda Margins -51.97 %
Trailing PE 0.8534 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.02 Target Low Price 7.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.9563 Open 1.03 Free Cashflow -17964750
State MA Dividend Yield 0.00 % Return On Assets -0.4024
Time Zone Short Name EST Trailing Eps 1.16 Day Low 0.9510
Address1 120 Presidential Way Shares Outstanding 7 M Price Hint 4
Target High Price 16.00 Website https://www.biofrontera-us.com 52 Week Change -0.7041
Average Volume 2 M Forward Eps -0.8600 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 85.20 % Last Split Factor 1:20
Regular Market Day High 1.05 Is_sp_500 False Profit Margins -38.34 %
Debt To Equity 13.20 Fifty Two Week High 4.00 Day High 1.05
Shares Short 457119 Regular Market Open 1.03 Industry Key drug-manufacturers-specialty-generic
Earnings Growth 0.00 % Enterprise To Revenue 0.0270 Revenue Growth 34.00 %
Shares Percent Shares Out 0.0825 Operating Cashflow -18915000 Currency USD
Time Zone Full Name America/New_York Market Cap 7 M Is_nasdaq_100 False
Zip 01801 Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic
Long Name Biofrontera Inc. Regular Market Day Low 0.9510 Held Percent Institutions 0.2068
Current Price 0.9900 Address2 Suite 330 Enterprise To Ebitda -0.0520
Financial Currency USD Current Ratio 1.89 Gross Margins 47.74 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 2 Country United States
Float Shares 2 M Two Hundred Day Average 1.16 Enterprise Value 959180
Price To Sales Trailing12 Months 0.2177 Forward PE -0.8609 Regular Market Volume 605231
Ebitda -18316000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.

It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.

The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo.

The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.